Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities
- PMID: 33632029
- DOI: 10.1177/2472555221991104
Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities
Abstract
Targeted protein degradation (TPD) is a recent strategy, utilizing the cell's proteostasis machinery to deplete specific proteins. This represents a paradigm shift in early drug discovery, away from occupancy-driven to event-driven mechanisms.Recent efforts have focused on the development of proteolysis-targeting chimeras (PROTACs). These heterobifunctional molecules combine a target-specific binding moiety linked to an E3 ligase ligand and trigger selective ubiquitination of the target protein, marking it for proteasomal degradation. While these molecules can be highly efficacious, they generally have unfavorable physicochemical properties due to their large size.In contrast, smaller molecules that induce degradation could represent an attractive, simple option to overcoming the limitations of both traditional modulators and PROTACs. These molecules may have a range of mechanisms: recruitment of an E3 ligase (molecular glues), introduction of hydrophobic areas, or inducing local unfolding, each of which triggers degradation.We recently completed a high-throughput screen of 111,000 compounds in a cellular HiBiT assay in an effort to identify such molecules. Preliminary analysis indicates that we have been able to identify alternative small-molecule degraders. We highlight methods for triage, characterization, selectivity, and mode of action. In summary, we believe that these types of small-molecule degraders, which may possibly have more acceptable physicochemical properties than the inherently larger heterobifunctional molecules, are an exciting approach for inducing TPD, and we illustrate that a general screening approach can be successful in identifying useful start points for developing such molecules.
Keywords: PROTAC; cell-based screening; high-throughput screening; molecular glues; targeted degradation.
Similar articles
-
A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts.SLAS Discov. 2021 Apr;26(4):534-546. doi: 10.1177/2472555220984372. Epub 2021 Jan 15. SLAS Discov. 2021. PMID: 33445986 Review.
-
The Vital Role of Proteomics in Characterizing Novel Protein Degraders.SLAS Discov. 2021 Apr;26(4):518-523. doi: 10.1177/2472555220985776. Epub 2021 Feb 20. SLAS Discov. 2021. PMID: 33615886 Review.
-
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3. SLAS Discov. 2021. PMID: 33143537 Free PMC article. Review.
-
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics.SLAS Discov. 2021 Apr;26(4):503-517. doi: 10.1177/2472555220985049. Epub 2021 Jan 11. SLAS Discov. 2021. PMID: 33430712 Review.
-
Target Validation Using PROTACs: Applying the Four Pillars Framework.SLAS Discov. 2021 Apr;26(4):474-483. doi: 10.1177/2472555220979584. Epub 2020 Dec 17. SLAS Discov. 2021. PMID: 33334221 Review.
Cited by
-
PROTAC targeted protein degraders: the past is prologue.Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18. Nat Rev Drug Discov. 2022. PMID: 35042991 Free PMC article. Review.
-
The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants.Front Pharmacol. 2022 Oct 3;13:931772. doi: 10.3389/fphar.2022.931772. eCollection 2022. Front Pharmacol. 2022. PMID: 36263131 Free PMC article.
-
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.Int J Mol Sci. 2024 Oct 23;25(21):11384. doi: 10.3390/ijms252111384. Int J Mol Sci. 2024. PMID: 39518937 Free PMC article. Review.
-
Deciphering the mechanism of E3 ubiquitin ligases in plant responses to abiotic and biotic stresses and perspectives on PROTACs for crop resistance.Plant Biotechnol J. 2024 Oct;22(10):2811-2843. doi: 10.1111/pbi.14407. Epub 2024 Jun 12. Plant Biotechnol J. 2024. PMID: 38864414 Free PMC article. Review.
-
The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.Cancer Metastasis Rev. 2022 Dec;41(4):975-990. doi: 10.1007/s10555-022-10066-y. Epub 2022 Oct 14. Cancer Metastasis Rev. 2022. PMID: 36229710 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources